3D(6-acyl) PHAD

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 412668

CAS#: 252042-59-4

Description: 3D(6-acyl) PHAD is a synthetic monophosphoryl Lipid A available for use as an adjuvant in human vaccines.

Chemical Structure

3D(6-acyl) PHAD
CAS# 252042-59-4

Theoretical Analysis

MedKoo Cat#: 412668
Name: 3D(6-acyl) PHAD
CAS#: 252042-59-4
Chemical Formula: C96H184N3O21P
Exact Mass:
Molecular Weight: 1747.5
Elemental Analysis: C, 65.98; H, 10.61; N, 2.40; O, 19.23; P, 1.77

Price and Availability

Size Price Availability Quantity
1.0mg USD 450.0 2 Weeks
5.0mg USD 1450.0 2 Weeks
Bulk inquiry

Synonym: 3D(6-acyl) PHAD; Monophosphoryl Hexa-acyl Lipid A, 3-Deacyl

IUPAC/Chemical Name: ammonium (2R,3S,4R,5R,6R)-2-(hydroxymethyl)-5-((R)-3-(tetradecanoyloxy)tetradecanamido)-4-(((R)-3-(tetradecanoyloxy)tetradecanoyl)oxy)-6-(((2R,3S,4R,5R,6S)-3,4,6-trihydroxy-5-((R)-3-(tetradecanoyloxy)tetradecanamido)tetrahydro-2H-pyran-2-yl)methoxy)tetrahydro-2H-pyran-3-yl hydrogen phosphate


InChi Code: InChI=1S/C96H181N2O21P.H3N/c1-7-13-19-25-31-37-40-46-52-58-64-70-85(102)113-78(67-61-55-49-43-34-28-22-16-10-4)73-83(100)97-89-92(107)91(106)82(116-95(89)108)77-112-96-90(98-84(101)74-79(68-62-56-50-44-35-29-23-17-11-5)114-86(103)71-65-59-53-47-41-38-32-26-20-14-8-2)94(93(81(76-99)117-96)119-120(109,110)111)118-88(105)75-80(69-63-57-51-45-36-30-24-18-12-6)115-87(104)72-66-60-54-48-42-39-33-27-21-15-9-3;/h78-82,89-96,99,106-108H,7-77H2,1-6H3,(H,97,100)(H,98,101)(H2,109,110,111);1H3/t78-,79-,80-,81-,82-,89-,90-,91-,92-,93-,94-,95+,96-;/m1./s1


Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 1747.5 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

1: Lederhofer J, van Lent J, Bhoelan F, Karneva Z, de Haan A, Wilschut JC, Stegmann T. Development of a Virosomal RSV Vaccine Containing 3D-PHAD® Adjuvant: Formulation, Composition, and Long-Term Stability. Pharm Res. 2018 Jul 3;35(9):172. doi: 10.1007/s11095-018-2453-y. PMID: 29971500; PMCID: PMC6061504.

2: Taleghani N, Bozorg A, Azimi A, Zamani H. Immunogenicity of HPV and HBV vaccines: adjuvanticity of synthetic analogs of monophosphoryl lipid A combined with aluminum hydroxide. APMIS. 2019 Mar;127(3):150-157. doi: 10.1111/apm.12927. PMID: 30746792.

3: Hernandez A, Patil NK, Stothers CL, Luan L, McBride MA, Owen AM, Burelbach KR, Williams DL, Sherwood ER, Bohannon JK. Immunobiology and application of toll-like receptor 4 agonists to augment host resistance to infection. Pharmacol Res. 2019 Dec;150:104502. doi: 10.1016/j.phrs.2019.104502. Epub 2019 Nov 2. PMID: 31689522; PMCID: PMC6884699.

4: Cawlfield A, Genito CJ, Beck Z, Bergmann-Leitner ES, Bitzer AA, Soto K, Zou X, Hadiwidjojo SH, Gerbasi RV, Mullins AB, Noe A, Waters NC, Alving CR, Matyas GR, Dutta S. Safety, toxicity and immunogenicity of a malaria vaccine based on the circumsporozoite protein (FMP013) with the adjuvant army liposome formulation containing QS21 (ALFQ). Vaccine. 2019 Jun 27;37(29):3793-3803. doi: 10.1016/j.vaccine.2019.05.059. Epub 2019 May 28. PMID: 31151801.

5: Singh P, Beck Z, Matyas GR, Alving CR. Saturated phospholipids are required for nano- to micron-size transformation of cholesterol-containing liposomes upon QS21 addition. J Liposome Res. 2019 Sep;29(3):247-250. doi: 10.1080/08982104.2018.1538239. Epub 2018 Nov 23. PMID: 30350748.

6: Genito CJ, Beck Z, Phares TW, Kalle F, Limbach KJ, Stefaniak ME, Patterson NB, Bergmann-Leitner ES, Waters NC, Matyas GR, Alving CR, Dutta S. Liposomes containing monophosphoryl lipid A and QS-21 serve as an effective adjuvant for soluble circumsporozoite protein malaria vaccine FMP013. Vaccine. 2017 Jul 5;35(31):3865-3874. doi: 10.1016/j.vaccine.2017.05.070. Epub 2017 Jun 7. PMID: 28596090.